The Investor Relations website contains information about Ventyx Biosciences, Inc.'s business for stockholders, potential investors, and financial analysts.
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmu...
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmu...
NLPR3 (Bioagelabs & Ventyx Bio pipeline)APJ。$Ventyx Biosciences(VTYX)$ 暴涨查看全文 讨论 chuminhua2023-11-08 11:51 11/7,Ventyx Biosciences $Ventyx Biosciences(VTYX)$ 宣布将终止 VTX958 治疗斑块型银屑病和银屑病关节炎的 II 期试验,因为疗效结果不合格,该公司股价周二下跌 80%。 首席执行官 Raju...
--Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced financial results for the third quarter en
Ventyx Biosciences, Inc. recently announced positive data from the company’s Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of VTX2735, a peripheral NLRP3 inhibitor, and the first of two product candidates from its NLRP3 portfolio. ...